Taysha Gene Therapies, Inc. short interest in 2023
In 2023, Taysha Gene Therapies, Inc.'s disclosed short interest ran from 2.75% of shares outstanding on 13 Jan 2023 to 9.37% on 29 Dec 2023, a change of +6.62 percentage points. The year's high was 9.37% on 29 Dec 2023 and its low 1.14% on 15 Aug 2023, averaging 3.87% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.15 days on 29 Dec 2023. Full history: Taysha Gene Therapies, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 2.75% (13 Jan 2023)
- End of year
- 9.37% (29 Dec 2023)
- Change
- +6.62 pp
- High
- 9.37% (29 Dec 2023)
- Low
- 1.14% (15 Aug 2023)
- Average
- 3.87%
- Highest days to cover
- 10.15 (29 Dec 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 2.75% | 4.51 | |
| 31 Jan 2023 | 3.49% | 4.03 | |
| 15 Feb 2023 | 3.58% | 2.07 | |
| 28 Feb 2023 | 4.27% | 7.47 | |
| 15 Mar 2023 | 3.77% | 9.67 | |
| 31 Mar 2023 | 3.04% | 3.31 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 2.57% | 2.56 | |
| 28 Apr 2023 | 2.72% | 4.59 | |
| 15 May 2023 | 1.87% | 4.61 | 10-Q filed, results (8-K) |
| 31 May 2023 | 1.93% | 4.86 | |
| 15 Jun 2023 | 2.25% | 7.37 | |
| 30 Jun 2023 | 2.02% | 2.68 | |
| 14 Jul 2023 | 1.77% | 6.02 | |
| 31 Jul 2023 | 1.73% | 7.34 | |
| 15 Aug 2023 | 1.14% | 1.00 | 10-Q filed, results (8-K) |
| 15 Nov 2023 | 7.46% | 3.90 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 8.64% | 7.98 | |
| 15 Dec 2023 | 9.16% | 8.09 | |
| 29 Dec 2023 | 9.37% | 10.15 |
See also: Taysha Gene Therapies, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.